Chloroquine Dosage

The information at Drugs.com is not a substitute for medical advice. ALWAYS consult your doctor or pharmacist.

Usual Adult Dose for:

Usual Pediatric Dose for:

Additional dosage information:

Usual Adult Dose for Malaria Prophylaxis

500 mg chloroquine phosphate (300 mg base) orally on the same day each week

Comments:
-If possible, suppressive therapy should start 2 weeks prior to exposure; if unable to start 2 weeks before exposure, an initial loading dose of 1 g chloroquine phosphate (600 mg base) may be taken orally in 2 divided doses, 6 hours apart.
-Suppressive therapy should continue for 8 weeks after leaving the endemic area.

Approved indication: For the suppressive treatment of malaria due to Plasmodium vivax, P malariae, P ovale, and susceptible strains of P falciparum

CDC Recommendations:
300 mg base (500 mg salt) orally once a week

Comments:
-For prophylaxis only in areas with chloroquine-sensitive malaria
-Prophylaxis should start 1 to 2 weeks before travel to malarious areas; should continue weekly (same day each week) while in malarious areas and for 4 weeks after leaving such areas.

Usual Adult Dose for Malaria

60 kg or more: 1 g chloroquine phosphate (600 mg base) orally as an initial dose, followed by 500 mg chloroquine phosphate (300 mg base) orally after 6 to 8 hours, then 500 mg chloroquine phosphate (300 mg base) orally once a day on the next 2 consecutive days
Total dose: 2.5 g chloroquine phosphate (1.5 g base) in 3 days

Less than 60 kg:
First dose: 16.7 mg chloroquine phosphate/kg (10 mg base/kg) orally
Second dose (6 hours after first dose): 8.3 mg chloroquine phosphate/kg (5 mg base/kg) orally
Third dose (24 hours after first dose): 8.3 mg chloroquine phosphate/kg (5 mg base/kg) orally
Fourth dose (36 hours after first dose): 8.3 mg chloroquine phosphate/kg (5 mg base/kg) orally
Total dose: 41.7 mg chloroquine phosphate/kg (25 mg base/kg) in 3 days

Comments:
-Concomitant therapy with an 8-aminoquinoline compound is necessary for radical cure of malaria due to P vivax and P malariae.

Approved indication: For acute attacks of malaria due to P vivax, P malariae, P ovale, and susceptible strains of P falciparum

CDC Recommendations:
Chloroquine-sensitive uncomplicated malaria (Plasmodium species or species not identified): 600 mg base (1 g salt) orally at once, followed by 300 mg base (500 mg salt) orally at 6, 24, and 48 hours
Total dose: 1.5 g base (2.5 g salt)

Comments:
-For the treatment of uncomplicated malaria due to chloroquine-sensitive P vivax or P ovale, concomitant treatment with primaquine phosphate is recommended.
-Current guidelines should be consulted for additional information.

Usual Adult Dose for Amebiasis

1 g chloroquine phosphate (600 mg base) orally once a day for 2 days, followed by 500 mg chloroquine phosphate (300 mg base) orally once a day for at least 2 to 3 weeks

Comments:
-Treatment is usually combined with an effective intestinal amebicide.

Approved indication: For the treatment of extraintestinal amebiasis

Usual Adult Dose for Sarcoidosis

(Not approved by FDA)

Study (n=43)
Intrathoracic and cutaneous: 250 mg twice a day for 4 to 17 months; a treatment course should be limited to 6 months to minimize risk of ocular damage

Study (n=23)
Pulmonary: 750 mg per day for 6 months, then tapered every 2 months to 250 mg per day

Study (n=37)
Nervous system (neurosarcoidosis): 250 mg twice a day for 6 to 18 months

Usual Pediatric Dose for Malaria Prophylaxis

Infants and children: 8.3 mg chloroquine phosphate/kg (5 mg base/kg) orally on the same day each week

Comments:
-Pediatric dose should not exceed the adult dose regardless of weight.
-If possible, suppressive therapy should start 2 weeks prior to exposure; if unable to start 2 weeks before exposure, an initial loading dose of 16.7 mg chloroquine phosphate/kg (10 mg base/kg) may be taken orally in 2 divided doses, 6 hours apart.
-Suppressive therapy should continue for 8 weeks after leaving the endemic area.

Approved indication: For the suppressive treatment of malaria due to P vivax, P malariae, P ovale, and susceptible strains of P falciparum

CDC Recommendations:
5 mg base/kg (8.4 mg salt/kg) orally once a week
Maximum dose: 300 mg base/dose (500 mg salt/dose)

Comments:
-For prophylaxis only in areas with chloroquine-sensitive malaria
-Prophylaxis should start 1 to 2 weeks before travel to malarious areas; should continue weekly (same day each week) while in malarious areas and for 4 weeks after leaving such areas.

Usual Pediatric Dose for Malaria

Infants and children:
Less than 60 kg:
First dose: 16.7 mg chloroquine phosphate/kg (10 mg base/kg) orally
Second dose (6 hours after first dose): 8.3 mg chloroquine phosphate/kg (5 mg base/kg) orally
Third dose (24 hours after first dose): 8.3 mg chloroquine phosphate/kg (5 mg base/kg) orally
Fourth dose (36 hours after first dose): 8.3 mg chloroquine phosphate/kg (5 mg base/kg) orally
Total dose: 41.7 mg chloroquine phosphate/kg (25 mg base/kg) in 3 days

60 kg or more:
First dose: 1 g chloroquine phosphate (600 mg base) orally
Second dose (6 hours after first dose): 500 mg chloroquine phosphate (300 mg base) orally
Third dose (24 hours after first dose): 500 mg chloroquine phosphate (300 mg base) orally
Fourth dose (36 hours after first dose): 500 mg chloroquine phosphate (300 mg base) orally
Total dose: 2.5 g chloroquine phosphate (1.5 g base) in 3 days

Comments:
-Concomitant therapy with an 8-aminoquinoline compound is necessary for radical cure of malaria due to P vivax and P malariae.

Approved indication: For acute attacks of malaria due to P vivax, P malariae, P ovale, and susceptible strains of P falciparum

CDC Recommendations:
Chloroquine-sensitive uncomplicated malaria (Plasmodium species or species not identified): 10 mg base/kg orally at once, followed by 5 mg base/kg orally at 6, 24, and 48 hours
Total dose: 25 mg base/kg

Comments:
-Pediatric dose should never exceed adult dose.
-For the treatment of uncomplicated malaria due to chloroquine-sensitive P vivax or P ovale, concomitant treatment with primaquine phosphate is recommended.
-Current guidelines should be consulted for additional information.

Renal Dose Adjustments

Data not available

Liver Dose Adjustments

Caution recommended in patients with hepatic disorders, alcoholism, or with concomitant hepatotoxic agents.

Precautions

Consult WARNINGS section for dosing related precautions.

Dialysis

Hemodialysis and peritoneal dialysis: Data not available

Comments:
-Peritoneal dialysis has been suggested to reduce the level of the drug in the blood.

Other Comments

General:
-The dose of chloroquine is often expressed or calculated as the base: each 500 mg tablet of chloroquine phosphate is equivalent to 300 mg chloroquine base.
-The pediatric dose should never exceed the adult dose.

Monitoring:
-Hematologic: Complete blood cell counts (periodically, if prolonged therapy)
-Musculoskeletal: For signs of muscular weakness (if prolonged therapy); knee and ankle reflexes (if prolonged therapy)
-Ocular: Ophthalmologic examinations, including visual acuity, expert slit-lamp, funduscopic, visual field tests (at baseline and periodically, if prolonged therapy considered)
-Renal: Renal function in patients with renal dysfunction

Hide
(web3)